<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071807</url>
  </required_header>
  <id_info>
    <org_study_id>PKE PECAN</org_study_id>
    <nct_id>NCT05071807</nct_id>
  </id_info>
  <brief_title>Cardiometabolic Effects of Pecans as a Snack</brief_title>
  <official_title>Cardiometabolic Effects of Including Pecans as a Snack to Improve Diet Quality: a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Pecan Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, 2-arm, parallel trial will be conducted to examine the effect of pecans on&#xD;
      markers of peripheral vascular health, lipids and lipoproteins, blood pressure, and glycemic&#xD;
      control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, 2-arm, parallel trial will be conducted to examine the effect of including 2&#xD;
      oz./day of pecans, as a snack, compared to a diet typically consumed by participants intake&#xD;
      (devoid of nuts) on markers of peripheral vascular health, lipids and lipoproteins, blood&#xD;
      pressure, and glycemic control. Participants will be randomized to pecans or control for&#xD;
      12-weeks. Outcome assessments will be measured at baseline and 12-weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Dilation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measured by brachial ultrasound and expressed as percent artery dilation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LDL-cholesterol concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed from fasting blood draw expressed in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-cholesterol concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed from fasting blood draw expressed in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed from fasting blood draw expressed in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL lipoprotein subclasses</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed from fasting blood draw expressed in nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL lipoprotein subclasses</measure>
    <time_frame>12 weeks</time_frame>
    <description>Assessed from fasting blood draw expressed in umol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brachial systolic and diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure measured assessed using a SphymoCor Ecel (Atcor Medical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central systolic and diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood pressure measured assessed using a SphymoCor Ecel (Atcor Medical)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid-femoral pulse wave velocity</measure>
    <time_frame>12 weeks</time_frame>
    <description>A measure of arterial stiffness assessed using a SphymoCor Ecel (Atcor Medical). Expressed in meters/second.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>A measure of arterial stiffness assessed using a SphymoCor Ecel (Atcor Medical). Expressed as a percentage. A higher percentage value is indicative of greater arterial stiffness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting blood glucose assessed by blood draw and expressed in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fasting serum insulin levels assessed by blood draw and expressed in micro IU/m</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12-weeks</time_frame>
    <description>HbA1c assessed in whole blood and expressed in micro IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diet quality: Healthy Eating Index 2015</measure>
    <time_frame>12-weeks</time_frame>
    <description>Diet quality measured by 24-hour recalls will be assessed using HEI-2015</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol concentration</measure>
    <time_frame>12-weeks</time_frame>
    <description>Assessed from fasting blood draw expressed in mg/dL</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the composition of the gut microbiota</measure>
    <time_frame>12 weeks</time_frame>
    <description>Abundance measured using 16 s rRNA sequencing</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Pecan Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will consume their usual diet, but replace one snack with unsalted raw pecans incorporated as a snack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will consume their usual diet devoid of nuts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pecans</intervention_name>
    <description>Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.</description>
    <arm_group_label>Pecan Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.</description>
    <arm_group_label>Usual Care Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 25-40 kg/m2&#xD;
&#xD;
          -  ≥ 1 criterion for metabolic syndrome (i.e., waist circumference ≥ 94 cm men or ≥ 80 cm&#xD;
             women; triglycerides ≥150 mg/dL; HDL-cholesterol ≤ 40 mg/dL men or ≤ 50 mg/dL women;&#xD;
             systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg; fasting plasma&#xD;
             glucose ≥100 mg/dL) at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of tobacco-containing products or (≤6 months) cessation&#xD;
&#xD;
          -  Allergy/sensitivity/intolerance/dislike of study foods&#xD;
&#xD;
          -  Women who are pregnant, lactating, planning to become pregnant or have given birth in&#xD;
             the past year&#xD;
&#xD;
          -  Individuals who have had a cardiovascular event (heart attack, revascularization,&#xD;
             stroke), or have a history of heart failure, liver, kidney, autoimmune diseases or&#xD;
             inflammatory conditions such as gastrointestinal disorders or rheumatoid arthritis.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes&#xD;
&#xD;
          -  Unstable weight ≥10% body weight for 6 months prior to enrollment&#xD;
&#xD;
          -  Systolic Blood pressure &gt;160 mmHg for systolic pressure and/or diastolic blood&#xD;
             pressure &gt;/100 mmHg for diastolic pressure at screening&#xD;
&#xD;
          -  Fasting blood glucose ≥126 mg/dL at screening&#xD;
&#xD;
          -  Triglycerides ≥350 mg/dL at screening&#xD;
&#xD;
          -  Taking any medications known to affect lipids, blood pressure, or blood glucose levels&#xD;
&#xD;
          -  Diagnosed inflammatory conditions or taking prescribed , taking any chronic&#xD;
             anti-inflammatory medications (&gt;1 time per week over the past 3 months)&#xD;
&#xD;
          -  Use of antibiotics within the prior 8 weeks&#xD;
&#xD;
          -  Taking supplements (e.g., psyllium, fish oil, soy lecithin, and phytoestrogens) and&#xD;
             botanicals known to affect study outcomes and not willing to cease for the duration of&#xD;
             the study&#xD;
&#xD;
          -  Individuals consuming &gt;14 alcoholic drinks/week, and not willing to avoid alcohol&#xD;
             consumption for 48 hours prior to test visit&#xD;
&#xD;
          -  Pre-menopausal women who do not have a regular menstrual cycle of 25-35 days&#xD;
&#xD;
          -  PI discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Penny Kris-Etherton, PhD</last_name>
    <phone>814-863-2923</phone>
    <email>pmk3@psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Arnold</last_name>
    <phone>814-863-8305</phone>
    <email>jqr9@psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Tricia L Hart, MS</last_name>
      <phone>866-778-3438</phone>
      <email>psudiet@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Penny M Kris-Etherton, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina S Petersen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

